media – Page 8 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Telportide outperforms semaglutide in all weight loss goals

After announcing its own weight loss drug more than five months ago, Telpotide beats Novo Nordisk in head-to-head battle After semaglutide, multinational pharmaceutical company Eli Lilly Detailed data from the head-to-head trial were released to the public. 　　On May 12, The Paper reporter learned that Eli Lilly announced the detailed results of the SURMOUNT-5 study. The results showed that at week 72, tepoxetine achieved the primary endpoint and all five key secondary endpoints, and showed superiority over semaglutide throughout the trial. 　　Specifically, in the primary endpoint of the study, tulpoide achieved a 1.47-fold relative weight loss compared to semaglutide. Research data based on the estimated target of the treatment regimen showed that at week 72, tulpoide achieved an average weight loss of 20.2%, while semaglutide was 13.7%. The average weight loss in the tulpoide group was 22.8kg, and the average weight loss in the semaglutide group ...
- Source: drugdu
- 57
- May 13, 2025
When AAV gene therapy becomes a “discarded plan”

Recently, Johnson & Johnson’s highly anticipated bota-vec therapy failed in the Phase III clinical trial, causing it to fall heavily from the limelight stage of AAV gene therapy. 1. Phase III clinical trial failure Recently, Johnson & Johnson, which has been making great strides in the field of gene therapy, has suffered a major setback. Its highly anticipated AAV gene therapy bota-vec failed to achieve the primary endpoint of improving patients’ visual navigation ability in the Phase III LUMEOS study for the treatment of X-linked retinitis pigmentosa (XLRP). This result not only makes the future of this star therapy, which has been certified by the FDA as both a fast track and orphan drug, uncertain, but also rings the alarm bell for the field of gene therapy. As a potential first-in-class gene therapy for XLRP, bota-vec uses an adeno-associated virus vector to deliver the retinitis pigmentosa GTPase regulator (RPGR) gene, ...
- Source: drugdu
- 50
- May 13, 2025
AstraZeneca’s big move

At AstraZeneca’s first quarter 2025 earnings conference, the pharmaceutical giant dropped a bombshell on its strategic adjustment: it will officially withdraw from the field of neuroscience and instead focus resources on core areas such as weight loss and immunology. 1. Cut the pipeline AstraZeneca’s first quarter 2025 financial report showed that the company had terminated the development of a number of neuroscience projects, including MEDI1814 for the treatment of Alzheimer’s disease developed in cooperation with Eli Lilly, MEDI0618, a migraine monoclonal antibody in Phase 2 clinical trials, and MEDI7352, a dual-antibody for the treatment of diabetic neuropathy. At this point, the company’s neuroscience pipeline under development has been reduced to zero. Image source: AstraZeneca 2025 Q1 financial report The field of neuroscience is recognized as a challenging “R&D black hole” due to the extreme complexity of the brain and nervous system and the unclear pathogenesis, which leads to low clinical ...
- Source: drugdu
- 48
- May 13, 2025
CPhI China

Organiser：Informa Markets Time：June 24-26, 2025 address：Longyang Road, Pudong New Area, Shanghai Exhibition hall：Shanghai New International Expo Centre, 2345 Product range: Pharmaceutical Raw Materials Zone (E1-E2, E6-E7, E9-E12 Halls): Vitamins, Tetracyclines, Penicillins, Cephalosporins, Hormones, Amino Acids and Derivatives, Aminoglycosides, Macrolides, Lincomycins, Respiratory Drugs, Antipyretic Analgesics, Digestive System Drugs, Cardiovascular System Drugs, Central Nervous System Drugs, Other Anti-infectives, Other Western Pharmaceutical Raw Materials, Pharmaceutical Intermediates, Pesticide Intermediates, Veterinary Drug Intermediates, Fine Chemicals, etc. Pharmaceutical Excipients Zone (E3, E6 Halls): Excipients, Glidants, Enteric Materials, Antioxidants, Sweeteners, Preservatives, Disintegrants, Coating Materials, Surfactants, Flavors, Filter Aids, Stabilizers, Lubricants, Plasticizers, Clarifying Agents, pH Regulators, etc. Formulations Zone (E3, E9 Halls): Chemical Drugs, Biopharmaceuticals, OEM Contract Manufacturing, Traditional Chinese Patent Medicines, Biological Products, Health Supplements, OTC Drugs, Ethnic Medicines Biotechnology Zone (W4, W8-W9 Halls) Biological Products and Emerging Therapies: Recombinant Proteins, Peptides, Nucleic Acids, Vaccines, Blood Products, Therapeutic Antibodies, Cell and Gene Therapy, Oncology Immunotherapy, Stem ...
- Source: drugdu
- 48
- May 13, 2025
【EXPERT Q&A】How to sterilize medical endoscopes?

Drugdu.com expert’s response: The sterilization of medical endoscopes requires the selection of appropriate methods based on their material, structure, and usage scenarios. Common sterilization methods and their operational key points are as follows: I. Selection of Sterilization Methods 1.Sterilization of Heat and Pressure-Resistant Instruments Applicable Objects: Rigid endoscopes made of stainless steel (e.g., laparoscopes, arthroscopes) and detachable metal components. Sterilization Method: Pressure steam sterilization (at 132°C and 2.1 bar for 3-5 minutes). Operational Key Points: Thoroughly remove organic matter, blood stains, and cleaning solution residues; sterilize in an exposed state (excluding drying time) and avoid stacking instruments; dry immediately after sterilization and hang vertically to prevent mirror surface scratches. 2.Sterilization of Heat-Sensitive Instruments (1) Low-Temperature Plasma Sterilization Applicable Objects: Flexible endoscopes (e.g., gastroscopes, colonoscopes) and optical components. Sterilization Method: Hydrogen peroxide low-temperature plasma sterilization (sterilization cycle of 45-75 minutes). Operational Key Points: Ensure instruments are completely dry before sterilization; follow ...
- Source: drugdu
- 50
- May 12, 2025
【EXPERT Q&A】Huadong Medicine’s marketing application for Semaglutide Injection has been accepted. What are the functions of this drug?

Drugdu.com expert’s response: The efficacy of Semaglutide Injection by East China Pharmaceutical is primarily reflected in the following aspects: Blood Glucose Control: Semaglutide Injection is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It stimulates insulin secretion in a glucose concentration-dependent manner, inhibits glucagon release, and delays gastric emptying, thereby effectively lowering blood glucose levels. It has significant effects on both fasting and postprandial blood glucose, helping patients with type 2 diabetes mellitus (T2DM) better control blood glucose fluctuations and reduce the damage caused by hyperglycemia. This medication is suitable for T2DM patients who have inadequate blood glucose control despite dietary and exercise modifications. It can significantly improve blood glucose indicators when used alone or in combination with other drugs. Weight Management: Semaglutide can suppress appetite by acting on the central nervous system to modulate neural signals related to food intake, thereby reducing food consumption. Additionally, it delays gastric emptying and ...
- Source: drugdu
- 56
- May 9, 2025
Bivalirudin for injection obtains marketing authorization from the Australian Therapeutic Goods Administration

One May 6, Shuangcheng pharma announced that the company recently received the marketing authorization for bivalirudin for injection issued by the Australian Therapeutic Goods Administration. The drug is used to treat patients with medium- and high-risk acute coronary syndrome (ACS) and can be used in combination with aspirin. Previously, the company had obtained the “Drug Registration Approval” approved and issued by the National Drug Administration for the drug, and passed the National Drug Administration’s injection generic drug quality and efficacy consistency evaluation. The Australian marketing authorization will have a positive impact on the company’s expansion of overseas markets and improvement of the company’s performance. However, the export business of drugs is affected by many factors, and there is uncertainty in the sales time, market size and subsequent expansion progress. https://finance.eastmoney.com/a/202505063396845130.html
- Source: drugdu
- 69
- May 8, 2025
HDM2005 for injection obtains drug clinical trial approval notice

Huadong Medicine announced on the evening of May 6 that its wholly-owned subsidiary Zhongmei Huadong received the “Notice of Approval for Drug Clinical Trial” approved and issued by the National Medical Products Administration (NMPA). The clinical trial application for HDM2005 for injection submitted by Zhongmei Huadong was approved. This product is combined with rituximab, cyclophosphamide, doxorubicin (or epirubicin) and prednisone (R-CHP) to treat diffuse large B-cell lymphoma (DLBCL) that has not been previously treated with systemic treatment. https://finance.eastmoney.com/a/202505063396854169.html
- Source: drugdu
- 66
- May 8, 2025
The 10 billion-dollar ankylosing spondylitis market is undergoing a transformation

In January, Zhixiang Jintai’s Celicizumab Injection was approved for a new indication, becoming the first domestically produced IL-17A inhibitor approved for the AS indication in China; in March, Hengrui Medicine’s JAK1 inhibitor Amacitinib Tablets were approved for marketing, with ankylosing spondylitis as the first indication; then in April, another product of Hengrui Medicine – Fulanixzumab Injection became the second domestically produced IL-17A inhibitor approved for AS. The strong breakthrough of domestic innovative drugs represented by Hengrui Medicine has not only broken the long-term monopoly of similar imported drugs and provided Chinese AS patients with new treatment options, but also marked the transformation of domestic innovative drugs from “followers” to “game changers”, injecting new vitality into the tens of billions of AS drug treatment market. Billion-dollar drug treatment market Ankylosing spondylitis is a disease caused by autoimmune disorders that causes chronic inflammation of the joints of the body, mainly damaging the ...
- Source: drugdu
- 61
- May 8, 2025
The 100 billion yuan autoimmune disease prevention market, the next outbreak point

In the field of autoimmune therapy, traditional biologics have long dominated the market. Although classic drugs represented by Humira have significant therapeutic effects, they have limitations such as the need for frequent injections and potential risks of infection, which lead to low patient compliance. In sharp contrast, oral autoimmune drugs are rising rapidly and becoming the next explosion point in the industry due to their multiple advantages such as convenient home administration, no need for cold chain transportation, and controllable production costs. The next hot spot Globally, there are approximately 100 different types of autoimmune diseases, which can affect almost any part of the body, from the skin to the joints to the digestive system. Epidemiological data show that the patient population covered by major indications such as psoriasis, atopic dermatitis, and asthma has exceeded 100 million, constituting the core treatment needs in the autoimmune field. According to Frost & ...
- Source: drugdu
- 57
- May 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.